Table 1.
Side effects during anti-CD19-CAR T cell combined with PD-1 inhibitor therapy.
| Prior therapy | Day 4 | Day 7 | Day 14 | Day 28 | |
|---|---|---|---|---|---|
| CAR-T(%) | 0.00 | 0.67 | 9.01 | 3.94 | 0.83 |
| IL-6(U/ml) | 3.10 | 7.02 | 13.76 | 6.05 | 3.13 |
| IL-2R(pg/ml) | 1.27 | 0.47 | 5.48 | 2.3 | 1.05 |
| IL-10(pg/ml) | 0.25 | 0.19 | 8.1 | 2.79 | 1.21 |
| TNF-α(pg/ml) | 1.02 | 0.89 | 4.07 | 1.35 | 1.36 |
| IFN-γ(pg/ml) | 0.56 | 0.89 | 5.15 | 2.30 | 1.78 |
| CD3+T(%) | 95.8 | 95.4 | 93.7 | 89.4 | 90.31 |
| CD3+CD4+T(%) | 44.72 | 30.21 | 16.63 | 15.53 | 13.71 |
| CD3+CD8+T(%) | 52.42 | 62.25 | 72.38 | 70.47 | 79.65 |
| Treg(%) | 6.02 | 6.12 | 8.41 | 10.98 | 7.05 |
| Ferritin(ng/ml) | 1285 | 1720 | 1180 | 979 | 621 |
| Hb(g/L) | 107 | 112 | 108 | 106 | 107 |
| WBC(×109/L) | 4.05 | 5.2 | 7.23 | 8.35 | 6.52 |
| PLT(×109/L) | 103 | 95 | 34 | 229 | 240 |